RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Nurix Therapeutics (NASDAQ:NRIX), but lowered the price target from $29 to $24.
November 02, 2023 | 5:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained an 'Outperform' rating on Nurix Therapeutics, but lowered the price target from $29 to $24.
The news is directly related to Nurix Therapeutics and is likely to influence investor sentiment. While the 'Outperform' rating is positive, the lowering of the price target may have a neutralizing effect. The overall impact on the stock price in the short term is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100